Phase II randomized study of immunotherapy of advanced breast cancer by repeated intramuscular injection of a recombinant vaccinia virus containing sequences coding for human MUC-1 and interleukin-2 (TG1031) comparing two doses levels

×

Error message

  • Notice: Trying to access array offset on value of type null in bootstrap_pager() (line 53 of /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
  • Notice: Trying to access array offset on value of type null in bootstrap_pager() (line 95 of /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
Study title: 
Phase II randomized study of immunotherapy of advanced breast cancer by repeated intramuscular injection of a recombinant vaccinia virus containing sequences coding for human MUC-1 and interleukin-2 (TG1031) comparing two doses levels
Date receipt dossier: 
4 Jun 1998
Pharmaceutical study code: 
TG1031.02
Company / Sponsor: 
Transgene
Phase: 
II
Treated organism: 
Humans
Indication category: 
Cancer therapy
Disease: 
Metastatic adenocarcinoma of the Breast
Therapeutic approach: 
Immunotherapy
Genetic modification: 
Muc-1 and Interleukine 2 (IL-2)
Method of transfer of nucleic acid of interest: 
Attenuated Vaccinia Virus (Copenhagen Strain)
Administered biological material: 
Recombinant Attenuated Vaccinia Virus
Route of administration: 
Intramuscular
Locations in Belgium: 
Universitair Ziekenhuis Gent
Type of procedure: 
Contained use only
Current status: 
Authorized